Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YTS109 Cell in Relapsed/Refractory Autoimmune Diseases
NCT06978647Phase 1Recruiting
- Sponsor
- China Immunotech
- Start
- May 2025
- Primary completion
- May 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of YTS-109 in systemic lupus erythematosus (SLE), systemic sclerosis (SSc), inflammatory myopathy (IIM) and 5 more, sponsored by China Immunotech. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 52 weeks. Started May 2025; status: recruiting.
02
Drugs
YTS-109
03
Conditions
systemic lupus erythematosus (SLE)systemic sclerosis (SSc)inflammatory myopathy (IIM)anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)antiphospholipid syndrome (APS)
Beyond the preview
Go deeper on NCT06978647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06978647.